drugset / Trial / NCT03757130

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

NCT03757130

Phase 1 Completed 50 enrolled Amgen
RandomizedSequentialDouble-blindOther

Summary

The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.

Timeline

Start
2018-11-26
Primary completion
2019-12-16
Completion
2019-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 598 Unknown 70 mg Subcutaneous
Subject AMG 598 Unknown 210 mg Subcutaneous
Subject AMG 598 Unknown 420 mg Subcutaneous
Background Liraglutide Peptide 3 mg Subcutaneous

Indications